Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs The Coca-Cola Co K (KO) Price & Performance

Adaptive Biotechnologies CorpTrade
The Coca-Cola Co KTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs The Coca-Cola Co K — how do they compare? Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B), while The Coca-Cola Co K trades at $86.55 (market cap $373.76B). The key difference: The Coca-Cola Co K is far larger — about 92.3× Adaptive Biotechnologies Corp's market cap, and The Coca-Cola Co K pays a 2.44% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.

ADPTKO
Market Cap
$4.05B$373.76B
Sector
HealthConsumer Staples
52-Week High
$25.45$89.08
52-Week Low
$12.30$65.67
Enterprise Value
$4.12B$400.93B
Volume
14,630,257
Dividend Yield
2.44%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.

Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.

The Coca-Cola Co K

Coca-Cola (KO) trades at $86.87, down 0.21% on the day, with a bullish technical signal supported by moving averages and RSI near oversold levels. The company shows strong profitability with a 28.56% net income margin and consistent earnings beats, while analyst consensus is a Buy with a $95.83 price target. Recent news highlights institutional accumulation and stable dividend trends.

The outlook remains positive given earnings momentum and dividend reliability, though risks include regional demand divergence and high valuation multiples. Upside is supported by analyst targets and institutional confidence, but investors should weigh debt levels and competitive pressures in the beverage sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About The Coca-Cola Co K

The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.

Read more on KO